PTPRG and chronic myelogenous leukemia, BCR-ABL1 positive: In our previous work, we demonstrated that the PTPRG promoter is methylated and that 55% of leukocytes from CML patients treated with TKI showed demethylation of the region and a re-expression of PTPRG [12].